177477-46-2

Upstream product

• 6160-65-2 1,1'-Thiocarbonyldiimidazole 
• 177478-40-9 3-[2,6-Dimethyl-3-[N-[4-(methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzyloxy]-2-amino-N-methylaniline 
• 177477-96-2 4-{(E)-2-[({[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-methyl-carbamoyl}-methyl)-carbamoyl]-vinyl}-N-methyl-benzamide 
• 174298-71-6 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-N-methyl-acetamide 
• 174298-70-5 N-[3-(tert-Butyl-diphenyl-silanyloxymethyl)-2,4-dimethyl-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide 
• 174298-72-7 3-(N-Glycyl-N-methylamino)-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 177477-98-4 1-chloromethyl-2,6-dimethyl-3-[N-[4-(methylcarbamoyl)cinnamoylglycyl]-N-methylamino]benzene 
• 177477-97-3 1-Hydroxymethyl-2,6-dimethyl-3-[N-[4-(methylcarbamoyl)-cinnamoylglycyl]-N-methylamino]benzene 
• 174298-68-1 tert-Butyl-(2,6-dimethyl-3-nitro-benzyloxy)-diphenyl-silane 
• 177477-65-5 tert-Butyl N-(3-benzyloxy-2-nitrophenyl)-N-methylcarbamate 
• 177477-63-3 tert-butyl 3-(benzyloxy)-2-nitrophenylcarbamate 
• 174298-69-2 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dimethylbenzene 
• 177477-68-8 3-benzyloxy-N-methyl-2-nitroaniline 
• 82617-30-9 (2,6-dimethyl-3-nitrophenyl)methyl acetate 

Relevant academic research and scientific papers

Benzimidazole compounds as bradykinin antagonists

PCT No. PCT/JP95/01478 Sec. 371 Date Feb. 3, 1997 Sec. 102(e) Date Feb. 3, 1997 PCT Filed Jul. 25, 1995 PCT Pub. No. WO96/04251 PCT Pub. Date Feb. 15, 1996This invention relates to a heterocyclic compound of the formula: wherein a group of the formula: is a group of the formula: etc., X is O, S or N-R5, R1 is lower alkyl, etc., R5 is hydrogen, lower alkyl, etc., R2 is hydrogen, halogen, lower alkyl, etc., R3 is halogen, lower alkyl, etc., R4 is amino optionally having suitable substituent(s), and A is lower alkylene, and a salt thereof, to processes for preparation thereof, and to a pharmaceutical composition comprising the same for the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]